Laurus Labs Ltd

LAURUSLABS

Company Profile

  • Business description

    Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.

  • Contact

    Road No. 7, Banjara Hills
    2nd Floor, Serene Chambers
    HyderabadTG500034
    IND

    T: +91 4039804333

    https://www.lauruslabs.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2026

    Employees

    12,467

Stocks News & Analysis

stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.
stocks

Coca-Cola earnings: Innovation and brand strength underpin growth

We plan to raise our fair value estimate of Coca-Cola stock.
stocks

Going into earnings, is Netflix stock a buy, a sell, or fairly valued?

Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,321.1010.80-0.12%
CAC 408,243.8415.02-0.18%
DAX 4024,316.2513.78-0.06%
Dow JONES (US)46,924.74218.160.47%
FTSE 1009,514.3287.330.93%
HKSE25,781.77245.78-0.94%
NASDAQ22,953.6736.88-0.16%
Nikkei 22549,307.798.27-0.02%
NZX 50 Index13,306.4471.41-0.53%
S&P 5006,735.350.220.00%
S&P/ASX 2009,030.0010.30-0.11%
SSE Composite Index3,913.762.57-0.07%

Market Movers